Exploration of Endocrine and Metabolic Diseases

Table 1. Effect of treatment on body weight and the glycemic status of diabetic rats.

Item	Groups
Item	NC	DC	NGN-D	GD-D	p-value
Initial BW (g)	161.07 ± 1.89	169.15 ± 1.33	165.36 ± 1.81	167.17 ± 1.48	p > 0.05
Final BW (g)	200.15 ± 2.29	146.41 ± 2.45^a	209.4 ± 2.31^b	206.94 ± 3.84^b	p < 0.01
Weight gain	41.08 ± 0.41	–23.74 ± 2.12^a	44.04 ± 0. 5^b	39.77 ± 2.36^b	p < 0.01
Glucose (mg/dL)	68.47 ± 5.12	229.17 ± 8.13^a	72.08 ± 4.13^b	74.91 ± 4.41^b	p < 0.01
Insulin (μU/mL)	17.44 ± 2.19	7.17 ± 0.81^a	19.08 ± 1.54^b	21.11 ± 2.53^b	p < 0.01

Return to article view

Data are expressed as means ± SEM of 10 rats/group. Initial and final body weight (BW) were measured, and weight gain was calculated. ^a Significantly different from the NC group (p < 0.01); ^b Significantly different from the DC group (p < 0.01). DC: diabetic control; GD-D: glimepiride-treated diabetic rats; NC: normal control; NGN-D: naringin-treated diabetic rats.

Declarations

Author contributions

OMM: Conceptualization, Methodology, Data curation, Formal analysis, Investigation, Writing—review & editing. AE: Conceptualization, Methodology, Data curation, Formal analysis, Writing—original draft, Writing—review & editing. BHE: Conceptualization, Data curation, Formal analysis, Writing—review & editing. MGMH: Methodology, Investigation. MAMA: Methodology, Writing—original draft. MRE: Methodology, Writing—original draft. AMH: Methodology, Investigation. NMG: Methodology, Investigation, Writing—original draft. AIS: Methodology, Writing—original draft. ASAEM: Methodology, Investigation. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical approval

The animal study protocol has been approved by the Ethical Review Committee of the Faculty of Medicine, Al-Azhar University, Damietta, Egypt (DFM-IRB 00012398-11-03-002). All procedures were performed in strict accordance with international standards for the care and treatment of laboratory animals.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

The datasets supporting the findings of this study are available from the corresponding author upon reasonable request.

Funding

The authors would like to acknowledge the Deanship of Graduate Studies and Scientific Research, Taif University, for funding this work. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: An overview. Avicenna J Med. 2020;10:174–88. [DOI] [PubMed] [PMC]

Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian J Endocrinol Metab. 2016;20:546–51. [DOI] [PubMed] [PMC]

Liu Y, Cai X, Shi B, Mo Y, Zhang J, Luo W, et al. Mechanisms and Therapeutic Prospects of Microglia-Astrocyte Interactions in Neuropathic Pain Following Spinal Cord Injury. Mol Neurobiol. 2025;62:4654–76. [DOI] [PubMed]

Said G. Diabetic neuropathy—a review. Nat Clin Pract Neurol. 2007;3:331–40. [DOI] [PubMed]

Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci. 2016;5:e47. [DOI] [PubMed] [PMC]

Danihelová M, Viskupičová J, Šturdík E. Lipophilization of flavonoids for their food, therapeutic and cosmetic applications. Acta Chim Slovaca. 2012;5:59–69. [DOI]

Villela A, van Vuuren MS, Willemen HM, Derksen GC, van Beek TA. Photo-stability of a flavonoid dye in presence of aluminium ions. Dyes Pigments. 2019;162:222–31. [DOI]

Xue Z, Wang J, Chen Z, Ma Q, Guo Q, Gao X, et al. Antioxidant, antihypertensive, and anticancer activities of the flavonoid fractions from green, oolong, and black tea infusion waste. J Food Biochem. 2018;42:e12690. [DOI]

Ullah A, Munir S, Badshah SL, Khan N, Ghani L, Poulson BG, et al. Important Flavonoids and Their Role as a Therapeutic Agent. Molecules. 2020;25:5243. [DOI] [PubMed] [PMC]

10.

Aguiar LM, Geraldi MV, Betim Cazarin CB, Maróstica Junior MR. Functional Food Consumption and Its Physiological Effects. Bioact Compd. 2019:205–25. [DOI]

11.

Nabavi SM, Šamec D, Tomczyk M, Milella L, Russo D, Habtemariam S, et al. Flavonoid biosynthetic pathways in plants: Versatile targets for metabolic engineering. Biotechnol Adv. 2020;38:107316. [DOI] [PubMed]

12.

Zeng X, Su W, Zheng Y, He Y, He Y, Rao H, et al. Pharmacokinetics, Tissue Distribution, Metabolism, and Excretion of Naringin in Aged Rats. Front Pharmacol. 2019;10:34. [DOI] [PubMed] [PMC]

13.

Cai J, Wen H, Zhou H, Zhang D, Lan D, Liu S, et al. Naringenin: A flavanone with anti-inflammatory and anti-infective properties. Biomed Pharmacother. 2023;164:114990. [DOI] [PubMed]

14.

Ghanbari-Movahed M, Jackson G, Farzaei MH, Bishayee A. A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies. Front Pharmacol. 2021;12:639840. [DOI] [PubMed] [PMC]

15.

Ito M, Kondo Y, Nakatani A, Hayashi K, Naruse A. Characterization of low dose streptozotocin-induced progressive diabetes in mice. Environ Toxicol Pharmacol. 2001;9:71–8. [DOI] [PubMed]

16.

Ahmad MF, Naseem N, Rahman I, Imam N, Younus H, Pandey SK, et al. Naringin Attenuates the Diabetic Neuropathy in STZ-Induced Type 2 Diabetic Wistar Rats. Life. 2022;12:2111. [DOI] [PubMed] [PMC]

17.

Pengnet S, Sumarithum P, Phongnu N, Prommaouan S, Kantip N, Phoungpetchara I, et al. Naringin attenuates fructose-induced NAFLD progression in rats through reducing endogenous triglyceride synthesis and activating the Nrf2/HO-1 pathway. Front Pharmacol. 2022;13:1049818. [DOI] [PubMed] [PMC]

18.

Yassen NN, Salama AA. Cytoprotectant Effect of Morus alba against Streptozotocin-Induced Diabetic Damage in Rat Brains. Pharma Chem. 2017;9:24–30.

19.

Koc A, Duru M, Ciralik H, Akcan R, Sogut S. Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats. Mol Cell Biochem. 2005;278:79–84. [DOI] [PubMed]

20.

Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–8. [DOI] [PubMed]

21.

Marklund S, Marklund G. Involvement of the Superoxide Anion Radical in the Autoxidation of Pyrogallol and a Convenient Assay for Superoxide Dismutase. Eur J Biochem. 2005;47:469–74. [DOI] [PubMed]

22.

Montgomery HAC, Dymock J. The determination of nitrite in water. Analyst. 1961;86:414–6.

23.

Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121–6. [DOI] [PubMed]

24.

Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70:158–69. [PubMed]

25.

Factor VM, Kiss A, Woitach JT, Wirth PJ, Thorgeirsson SS. Disruption of Redox Homeostasis in the Transforming Growth Factor-α/c-myc Transgenic Mouse Model of Accelerated Hepatocarcinogenesis. J Biol Chem. 1998;273:15846–53. [DOI] [PubMed]

26.

Bilkei-Gorzo A, Abo-Salem OM, Hayallah AM, Michel K, Müller CE, Zimmer A. Adenosine receptor subtype-selective antagonists in inflammation and hyperalgesia. Naunyn-Schmiedeb Arch Pharmacol. 2008;377:65–76. [DOI] [PubMed]

27.

Abo-Salem OM, Ali TM, Harisa GI, Mehanna OM, Younos IH, Almalki WH. Beneficial effects of (-)-epigallocatechin-3-O-gallate on diabetic peripheral neuropathy in the rat model. J Biochem Mol Toxicol. 2020;34:e22508. [DOI] [PubMed]

28.

Janssen PA, Niemegeers CJ, Dony JG. The inhibitory effect of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawl reflex in rats. Arzneimittelforschung. 1963:502–7. [PubMed]

29.

Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53:55–63. [DOI] [PubMed]

30.

Feldman EL, Nave KA, Jensen TS, Bennett DLH. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron. 2017;93:1296–313. [DOI] [PubMed] [PMC]

31.

Albers JW, Pop-Busui R. Diabetic Neuropathy: Mechanisms, Emerging Treatments, and Subtypes. Curr Neurol Neurosci Rep. 2014;14:473. [DOI] [PubMed] [PMC]

32.

Okesina KB, Odetayo AF, Adeyemi WJ, Okesina AA, Bassey GE, Olayaki LA. Naringin Prevents Diabetic-Induced Dysmetabolism in Male Wistar Rats by Modulating GSK-3 Activities and Oxidative Stress-Dependent Pathways. Cell Biochem Biophys. 2024;82:3559–71. [DOI] [PubMed]

33.

Barajas-Vega JL, Raffoul-Orozco AK, Hernandez-Molina D, Ávila-González AE, García-Cobian TA, Rubio-Arellano ED, et al. Naringin reduces body weight, plasma lipids and increases adiponectin levels in patients with dyslipidemia. Int J Vitam Nutr Res. 2022;92:292–8. [DOI] [PubMed]

34.

Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD. Effect of Citrus Flavonoids, Naringin and Naringenin, on Metabolic Syndrome and Their Mechanisms of Action. Adv Nutr. 2014;5:404–17. [DOI] [PubMed] [PMC]

35.

Ahmed OM, Mahmoud AM, Abdel-Moneim A, Ashour MB. Antidiabetic effects of hesperidin and naringin in type 2 diabetic rats. Diabetol Croat. 2012;41:53–67.

36.

Yu J, Wang Y, Qian H, Zhao Y, Liu B, Fu C. Polyprenols from the needles of Taxus chinensis var. mairei. Fitoterapia. 2012;83:831–7. [DOI] [PubMed]

37.

Oyindamola OA, Adewale GB, Christiana TA, Adebola IK, Tolulope AO, Tejumade SU. Naringin ameliorates cognitive impairment in streptozotocin/nicotinamide induced type 2 diabetes in Wistar rats. Physiol Pharmacol. 2022;26:20–9. [DOI]

38.

Shin HY, Kim SH, Jeong HJ, Kim SY, Shin TY, Um JY, et al. Epigallocatechin-3-Gallate Inhibits Secretion of TNF-α, IL-6 and IL-8 through the Attenuation of ERK and NF-κB in HMC-1 Cells. Int Arch Allergy Immunol. 2006;142:335–44. [DOI] [PubMed]

39.

Nashtahosseini Z, Eslami M, Paraandavaji E, Haraj A, Dowlat BF, Hosseinzadeh E, et al. Cytokine Signaling in Diabetic Neuropathy: A Key Player in Peripheral Nerve Damage. Biomedicines. 2025;13:589. [DOI] [PubMed] [PMC]

40.

Baskaran G, Salvamani S, Ahmad SA, Shaharuddin NA, Pattiram PD, Shukor MY. HMG-CoA reductase inhibitory activity and phytocomponent investigation of Basella alba leaf extract as a treatment for hypercholesterolemia. Drug Des Dev Ther. 2015;9:509–17. [DOI] [PubMed] [PMC]

41.

Hu CY, Zhao YT. Analgesic effects of naringenin in rats with spinal nerve ligation-induced neuropathic pain. Biomed Rep. 2014;2:569–73. [DOI] [PubMed] [PMC]

42.

Tsai SJ, Huang CS, Mong MC, Kam WY, Huang HY, Yin MC. Anti-inflammatory and Antifibrotic Effects of Naringenin in Diabetic Mice. J Agric Food Chem. 2011;60:514–21. [DOI] [PubMed]

43.

Zeghichi-Hamri S, de Lorgeril M, Salen P, Chibane M, de Leiris J, Boucher F, et al. Protective effect of dietary n-3 polyunsaturated fatty acids on myocardial resistance to ischemia-reperfusion injury in rats. Nutr Res. 2010;30:849–57. [DOI] [PubMed]

44.

A Bakheet S, M Attia S. Evaluation of Chromosomal Instability in Diabetic Rats Treated with Naringin. Oxidative Med Cell Longev. 2011;2011:365292. [DOI] [PubMed] [PMC]

45.

Mahmoud AM, Ashour MB, Abdel-Moneim A, Ahmed OM. Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fat fed/streptozotocin-induced type 2 diabetic rats. J Diabetes Complicat. 2012;26:483–90. [DOI] [PubMed]